Since MEK is rarely mutated in human cancer, it was not considered an effective target in the past, but with increasing knowledge of the role of the MAPK/ERK signaling in cancer, targeting MEK is attracting more and more attention [140]. The gene discussed is MAP2K7; the disease is cancer.